Khemistry Kraft
Would you like to react to this message? Create an account in a few clicks or log in to continue.

THE COVID-19 TIMELINE 1980 - 2020

Go down

THE COVID-19 TIMELINE 1980 - 2020 Empty THE COVID-19 TIMELINE 1980 - 2020

Post by Kerstin Sat Feb 13, 2021 9:13 pm

The greatest conspiracy of all times - and it's provable!

PART 1 the "Great Reset Technology"

(April 24, 2015) Oxford Nanopore: we want to create the internet of living things

Oxford Nanopore Technologies, Wellcome Trust, LamPORE test, "the internet of living things - real time connection of live DNA information".

Oxford Nanopore Technologies wants to get your DNA online, and that future is closer than you think. MinION, a £650 gene sequencer created by the company that plugs into USB ports, could soon be integrated into your mobile phone, CTO Clive Brown told the audience at WIRED Health 2015. "Our big dream is to move towards self quantification, and we're going to make a version that works on handheld mobile phones.

It can measure your blood markers and collate that data to track changes in your daily biology. Brown joined Oxford Nanopore in June 2008, having formerly worked at the UK's largest genomic laboratory, the Wellcome Trust Sanger Institute. Nanopores are tiny chips which sit on a silicon chip that can read what's happening in the hole, by reading the flow of ions through it, explained Brown. "As they move through the hole they generate an electronic signal characteristic of the DNA."

This can be read from a solution, like blood, very quickly and deliver real time DNA scanning in near real time.
MinION, fitted with a array of tiny holes 1.5 nanometers across, is the outcome of this technology. "I first held MinION three years ago," said Brown. "It's a fun-size DNA sequencer, and there are thousands out there in early testing. Most recently, a team took it to Guinea, to sequence Ebola. It takes 15 minutes per patient, and the team in Guinea is using it to track how a particular strain has spread. "You can run it anywhere on anything," said Brown, "and that opens it up to other applications. We can embed it in fridges or toothbrushes as it get smaller -- it can become a ubiquitous sensing apparatus."

(April 27, 2015) How knowing your genetic code could lengthen your life

Fifteen years ago this month, the full human genome sequence was published for the first time, heralding a new era of medicine. Since then technology has markedly speeded up genomic sequencing and reduced the cost. But have those hoped-for medical breakthroughs materialised? Sequencing the human genome took 10 years and cost about $3bn (£2.2bn). Now advances in computing power have seen the cost of human genome sequencing fall to under $500. A firm called Oxford Nanopore has even developed a hand-held reader that can sequence genetic material in minutes. Dr Gordon Sanghera, the firm's chief executive, talks about creating "the internet of living things - real time connection of live DNA information" using such portable devices.

Within the next 10 years, "everyone will get sequenced at birth", he says, and we'll be able to assess whether we have genetic dispositions to particular diseases and take preventative steps accordingly. "We are at the beginning of a revolution in healthcare," says Ruth March, vice-president and head of precision medicine and genomics at pharmaceutical company AstraZeneca. "We're fighting medical tradition where we wait until people are sick before we treat them," says Prof Venter. "The completion of the human genome project held out much hope for the better understanding and treatment of diseases. "But as is usually the case, we had underestimated the complexity of the relationship of genome to disease and health," concludes IBM's Laxmi Parida.

(December 1, 2016) Wellcome Trust Centre for Human Genetics and Genomics plc First to Sequence Multiple Human Genomes using hand-held Nanopore Technology

Oxford University’s Wellcome Trust Centre for Human Genetics (WTCHG) and the leading genome analytics company Genomics plc today announced the first sequencing and analysis of multiple human genomes using nanopore technology. Today’s announcement raises the possibility of a major change to both the economics and the science of DNA sequencing. Researchers at the WTCHG and Genomics plc used the MinION sequencer developed by Oxford Nanopore Technologies.

The portable MinION is a hand-held device about the size of a Mars bar, and is powered by a laptop computer to which it connects via a USB port. Recent upgrades to the technology have now made it possible for researchers to conduct larger-scale studies such as sequencing complete human genomes by using multiple MinIONs. A key strength of nanopore sequencing is that reads can be much longer than is possible with other scalable sequencing technologies. Longer reads offer significant advantages in human genome sequencing, enabling researchers to obtain good sequence data from certain biologically important regions of the genome which are difficult to study using existing sequencing technologies. The long reads also appear to make it easier to detect large structural changes in individual genomes.

(August 3, 2020) Oxford Nanopore Technologies partners with UK Government to roll out LamPORE, a new generation of COVID-19 test

Oxford Nanopore today announces an agreement with the UK’s Department of Health and Social Care, to roll out its novel LamPORE test. This will support the UK’s efforts to manage the continued reduction of COVID-19 and containment of new cases, now and through the winter cold and flu season. Under the agreement, an initial 450k LamPORE SARS-CoV-2 tests will be made available for use by a number of NHS testing laboratories. As well as providing a large number of tests for existing labs, the programme will help the UK to understand the different use cases for the technology, for example the potential asymptomatic screening of frontline staff. Because of its scalability, LamPORE has the potential to provide both: Large-scale screening to detect the virus in broader populations.

Individuals being tested may be presymptomatic or asymptomatic, eg:

-Regular screening of frontline workforces
-Broad screening of a community/population in the event of an outbreak
-Screening at the point of congregation eg transport hubs

LamPORE is designed to be deployed on Oxford Nanopore’s desktop device (GridION) or palm-sized device (MinION Mk1C), providing the capacity of processing up to 15,000 samples a day or 2,000 samples a day respectively. In addition to a test for SARS-CoV-2, the virus that causes COVID-19, Oxford Nanopore is currently developing LamPORE to test for multiple pathogens within a single sample, including influenza A (H1N1 and H3N2), influenza B, respiratory syncytial virus (RSV) and SARS-CoV-2.

(August 14, 2020) Researchers Use Nanopore Sequencing Technology to Complete First Gapless End-to-End Assembly of Human X Chromosome

Using nanopore sequencing technology from multiple companies, researchers at the University of California Santa Cruz Genomics Institute (UCSC Genomics Institute) have produced what they say is the first telomere-to-telomere or end-to-end map of the human X chromosome. This could prove to be a major milestone for genomics research and help scientists gain a better understanding of certain genetic conditions. The completely gapless DNA sequencing was produced by using new sequencing technologies that enable much longer reads of strings of DNA base pairs. In the past, most sequencing technologies produced relatively short reads of each sequence, which then had to be painstakingly pieced together to assemble the complete genome.

Nanopore sequencing technology from Oxford Nanopore Technologies was combined with sequencing technologies
from Pacific Biosciences (PacBio) and Illumina, as well as with optical maps from Bionano Genomics, to produce the results of the research. The combination of these technologies allowed the UCSC team to produce a whole-genome sequence assembly with no gaps and with a previously unforeseen level of accuracy. Besides the advantages of providing ultra-long reads, nanopore sequencing can also detect bases that have been modified by methylation, a biological process by which methyl groups are added to the DNA molecule. Methylation is an epigenetic change that can alter the activity of a DNA segment without changing the sequence, and can have important effects on the DNA structure and gene expression.

Last edited by Kerstin on Sun Feb 14, 2021 4:13 pm; edited 1 time in total

Posts : 85
Join date : 2020-09-18

Back to top Go down

THE COVID-19 TIMELINE 1980 - 2020 Empty Re: THE COVID-19 TIMELINE 1980 - 2020

Post by Kerstin Sat Feb 13, 2021 9:19 pm



(December 12, 1980) The Bayh–Dole Act

Sponsored by two senators, Birch Bayh (Democrat) of Indiana and Bob Dole (Republican) of Kansas the Act was adopted in 1980. A key change made by Bayh–Dole was in the procedures by which federal contractors (global pharma companies) that acquired ownership of inventions made with federal funding (taxpayers money) could retain that ownership. Before the Bayh–Dole Act, the Federal Procurement Regulation required the use of a patent rights clause that in some cases required federal contractors or their inventors to assign inventions made under contract to the federal government unless the funding agency determined that the public interest was better served by allowing the contractor or inventor to retain principal or exclusive rights.

(May 10, 1981) The Eyes of Darkness - a thriller novel written by American writer Dean Koontz.

The novel mentions a bioweapon that in earlier editions is called "Gorki-400" and in later editions was called "Wuhan-400". Gorki is a Russian city and named as the origin of that bioweapon in the 1981 edition. Due to the end of the Cold War, the origin of the bioweapon was changed to the Chinese city of Wuhan and the bioweapon was renamed "Wuhan-400" for the 2008 edition onward.

(March 8, 1992) U.S. Strategy Plan Calls For Insuring No Rivals Development.

A 46-page document that has been circulating at the highest levels of the Pentagon for weeks, and which Defense Secretary Dick Cheney expects to release later this month, states that part of the American mission will be "convincing potential competitors that they need not aspire to a greater role or pursue a more aggressive posture to protect their legitimate interests."

(February 1995) neo-Nazi Larry Wayne Harris ordered 3 vials of plague pathogen from the American Type Culture Collection, one of the largest collections of microorganisms in the world. In the same year, the extreme right-winger Timothy McVeigh carried out a bomb attack against a government building in Oklahoma City, killing more than 150 people.

(January 03, 1997) Donald H. Rumsfeld Named Chairman of Gilead Sciences

In 1997, Donald Rumsfeld was appointed Chairman of the Board of Gilead Sciences, a company which a year earlier had developed ‘Tamiflu’ (oseltamivir), originally a drug for AIDS and later marketed as a vaccine for H5N1 avian flu. Upon becoming US Defence Secretary in 2001, he ordered $1 billion worth of Tamiflu to be bought and injected into US soldiers as a ‘precaution’. At the time, Rumsfeld was the principal stockholder of Gilead Sciences. Worse still, it later emerged that Tamiflu was not even effective as a H5N1 vaccine.

(September 2000) PNAC released "Rebuilding America's Defenses"

A report that promotes "the belief that America should seek to preserve and extend its position of global leadership by maintaining the preeminence of U.S. military forces." (Introduction part IV)

The report also states, "advanced forms of biological warfare that can “target” specific genotypes may transform biological warfare from the realm of terror to a politically useful tool."(page 60)

"Further, the process of transformation, even if it brings revolutionary change, is likely to be a long one, absent some catastrophic and catalyzing event – like a new Pearl Harbor." (page 51)

(June 22-23, 2001) Dark Winter Exercise

Center for Strategic and International Studies, the Johns Hopkins Center for Civilian Biodefense Studies, the ANSER Institute for Homeland Security, and the Oklahoma City National Memorial Institute for the Prevention Terrorism, hosted a senior-level war game examining the national security, intergovernmental, and information challenges of a biological attack on the American homeland.

(September 3, 2001)Top scientist warns Britain to be prepared for biological warfare

Sir William, president of the British Association for the Advancement of Science, told fellow scientists: "There are those who say the First World War was chemical, the Second World War was nuclear, and that the third world war, God forbid, will be biological".

(September 11, 2001) Dancing Israelis

A New York resident referred to by ABC only as "Maria" reports that on the morning of 9/11, a neighbor called her shortly after the first plane hit the World Trade Center. She watched the destruction unfolding in lower Manhattan through binoculars and three young men kneeling on the roof of a white 2000 Chevrolet van in the parking lot of her apartment building caught her attention since "they seemed to be taking a movie". Particularly suspicious she found the expressions on the men's faces. "They were like happy, you know..."

(September 18, 2001) One week after the 9/11 attack

on the World Trade Center towers in New York City, letters containing anthrax bacteria were mailed to several news media offices and two U.S. Senators, ultimately killing five people and infecting 17 others.

During their investigation, the FBI concluded that Bruce Edward Ivins, a microbiologist for the United States Army, had mailed the deadly letters. The FBI obtained some of the anthrax spores and analyzed them. After analyzing the spores, the FBI traced the spores to a military lab located at Fort Detrick, Maryland.

(October 26, 2001) The USA PATRIOT Act of the United States Congress, signed into law by President George W. Bush

Those opposing the law have criticized its authorization of indefinite detentions of immigrants; the permission given to law enforcement to search a home or business without the owner's or the occupant's consent or knowledge; the expanded use of National Security Letters, which allows the Federal Bureau of Investigation (FBI) to search telephone, e-mail, and financial records without a court order; and the expanded access of law enforcement agencies to business records, including library and financial records.

Since its passage, several legal challenges have been brought against the act, and federal courts have ruled that a number of provisions are unconstitutional. Many of the act's provisions were to sunset beginning December 31, 2005, approximately four years after its passage. In the months preceding the sunset date, supporters of the act pushed to make its sun-setting provisions permanent, while critics sought to revise various sections to enhance civil liberty protections.

(January 25, 2002) NIH Budget Reaches Doubling Point

President George W. Bush will propose a National Institutes of Health (NIH) budget of $27.3 billion, a rise of almost 16% that represents a doubling since 1998. The sum is gratifying to biomedical lobbying groups, which have pushed hard to double the NIH budget over 5 years. But the victory isn't entirely sweet: The bulk of the new money in 2003 would go for bioterrorism, which means most of NIH's 27 institutes will likely get smaller increases.

(February 19, 2002) Bush Will Not Name AIDS Researcher Anthony Fauci as NIH Director

Unnamed Official says: abortion politics cited. The AP/Post-Dispatch reports that HHS Secretary Tommy Thompson (Republican politician) has been "pushing" for Fauci, who has been the director of NIH's National Institute of Allergy and Infectious Diseases since 1984

(July 12, 2002) Traces of Terror: The  Science; Scientists create a live Polio Virus

Scientists reported yesterday that they had constructed a virus from scratch for the first time, synthesizing a live polio virus from chemicals and publicly available genetic information. The work, conducted by scientists at the State University of New York at Stony Brook, was financed by the Pentagon as part of a program to develop bio warfare countermeasures. The scientists constructed the virus using its genome sequence,which is available on the Internet, as their blueprint and genetic material from one of the many companies that sell made-to-order DNA.

(November 16, 2002) First known case of SARS occurs in Foshan City, China

The WHO Beijing office receives an email message describing a “strange contagious disease” that has “already left more than 100 people dead” in Guangdong Province in the space of one week. The message further describes “a ‘panic’ attitude, currently, where people are emptying pharmaceutical stocks of any medicine they think may protect them.”

(October 2003) Ageless Bodies - The President Bush's Council on Bioethics

It may at first seem strange to suggest that we yearn for an "ageless body," not a term commonly heard and certainly not the conscious and explicit longing of very many people. Still, when properly examined, something like a desire for an "ageless body" seems in fact to be commonplace and deeply held; and should our capacities to retard the senescence of our bodies increase, that desire may well become more explicit and strong. In this sense, it is fundamentally the aging of the body we wish to stop. But it is more than the dread of decline that motivates us to seek ageless bodies. Different human societies have had very different conceptions of the divine, but one attribute has almost universally been attached to the gods: immortality. Our subjection to death-and our awareness of this fact-is central to what makes us human ("mortals") rather than divine, and it makes us fearful and weak and constrained.

(November 27, 2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Recently, a distinct coronavirus has been identified as the aetiological agent of SARS, an acute pulmonary syndrome characterized by an atypical pneumonia that results in progressive respiratory failure and death in close to 10% of cases. Analysis of the SARS-CoV genome suggests that this virus does not belong to any of the three defined coronavirus groups, and that the SARS-CoV S protein is similarly distinct. Similar to the analogous human immunodeficiency virus (HIV) and influenza proteins, the S proteins of some coronaviruses—including MHV and the group III coronavirus infectious bronchitis virus—are cleaved into two subunits (S1 and S2) by a cellular protease in virus-producing cells.

(October 5, 2005) An effort to recreate the 1918 flu strain

(A subtype of avian strain H1N1) was a collaboration among the Armed Forces Institute of Pathology, the USDA ARS Southeast Poultry Research Laboratory, and Mount Sinai School of Medicine in New York City. The effort resulted in the announcement (on 5 October 2005) that the group had successfully determined the virus's genetic sequence, using historic tissue samples recovered by pathologist Johan Hultin from a female flu victim buried in the Alaskan permafrost and samples preserved from American soldiers.

(May 20, 2007) Difference in Receptor Usage between Severe Acute Respiratory Syndrome (SARS) Coronavirus and SARS-Like Coronavirus of Bat Origin

In this study, we investigated the receptor usage of the SL-CoV S by combining a human immunodeficiency virus-based pseudovirus system with cell lines expressing the ACE2 molecules of human, civet, or horseshoe bat. In addition to full-length S of SL-CoV and SARS-CoV, a series of S chimeras was constructed by inserting different sequences of the SARS-CoV S into the SL-CoV S backbone.

This work was jointly funded by a State Key Program for Basic Research Grant (2005CB523004) from the Chinese Ministry of Science and Technology, a special fund from the president of the Chinese Academy of Sciences (no. 1009), the Knowledge Innovation Program Key Project of the Chinese Academy of Sciences (KSCX1-YW-R-07) to Z. Shi, the Sixth Framework Program “EPISARS” of the European Commission, a National Nature Science Foundation of China for Creative Research group grant (30421004) to H. Deng, and the Australian Biosecurity CRC for Emerging Infectious Diseases (project 1.026RE) to L.-F. Wang.

(December 16, 2008) Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice

Here, we report the design, synthesis, and recovery of the largest synthetic replicating life form, a 29.7-kb bat severe acute respiratory syndrome (SARS)-like coronavirus (Bat-SCoV), a likely progenitor to the SARS-CoV epidemic. To test a possible route of emergence from the noncultivable Bat-SCoV to human SARS-CoV, we designed a consensus Bat-SCoV genome and replaced the Bat-SCoV Spike receptor-binding domain (RBD) with the SARS-CoV RBD (Bat-SRBD). Bat-SRBD was infectious in cell culture and in mice and was efficiently neutralized by antibodies specific for both bat and human CoV Spike proteins.

Deleted original link :

"It can be very hard to study where a virus originally came from," said Mark Denison."If you start from where you think the virus was, and let the virus tell you where it's going, then you learn a tremendous amount about viral evolution and movement." Denison's team used the genetic sequence of bat SARS to build the virus. Bat SARS doesn't normally infect people, but the researchers added a critical tweak: a gene present only in the human version of the virus. The new version flourished in human cell cultures, suggesting that a mutation in the gene, known as Bat-SRBD, was responsible for SARS' lethal spread.

(December 20, 2011) Seeing Terror Risk, U.S. Asks Journals to Cut Flu Study Facts

In the experiments, conducted in the United States (Yoshihiro Kawaoka) and the Netherlands (Ron Fouchier),
scientists created a highly transmissible form of a deadly flu virus that does not normally spread from person to person.

(January 20, 2012) Fears of mutant virus escape halt bird flu study

Researchers studying a potentially more lethal, airborne version of the bird flu virus have suspended their studies because of concerns the mutant virus they have created could be used as a devastating form of bioterrorism or accidentally escape the lab.

Nature reported last month that both experiments on mutant viruses were carried out in labs rated “biosafety level 3 (BSL-3) enhanced,” which “require scientists to shower and change clothes when leaving the lab, and include other safety features such as negative air pressure and passing exhaust air through high-efficiency particulate air filters.”

But some virologists argue that the more stringent BSL-4 precautions are needed. BSL-4, which is required for research on, among other microbes, the Ebola virus, includes full-body positive air-pressure suits like astronauts use. In the past, the SARS (severe acute respiratory syndrome) virus has escaped from BSL-3, and possibly BSL-4, labs.

(May 2, 2012) Mutant-flu paper

published by Yoshihiro Kawaoka at the University of Wisconsin–Madison, a controversial study shows how dangerous forms of avian influenza could evolve in the wild. To find out if H5N1 could evolve easy transmissibility between humans, Kawaoka and his team mutated its haemagglutinin (HA) gene, which produces the protein that the virus uses to stick itself to host cells. Because flu viruses in the wild can also gain new properties by swapping genes, the researchers combined this gene with seven others from a highly transmissible flu virus, the H1N1 strain that caused a pandemic in 2009. Kawaoka found that the hybrid virus could spread between ferrets in separate cages after acquiring just four mutations.

(June 21, 2012) Second mutant-flu paper published by Ron Fouchier from the Erasmus Medical Centre in Rotterdam) Just five mutations allow H5N1 to spread between ferrets.


Posts : 85
Join date : 2020-09-18

Back to top Go down

THE COVID-19 TIMELINE 1980 - 2020 Empty Re: THE COVID-19 TIMELINE 1980 - 2020

Post by Kerstin Sat Feb 13, 2021 9:20 pm


(January 23, 2013) H5N1 Researchers Announce End of Research Moratorium

In a teleconference today, the letter's lead author said he does not expect researchers to be able to begin studies immediately. "It takes time to shut down research, and it takes time to start it back up," said virologist Ron Fouchier of Erasmus MRC in Rotterdam, the Netherlands, who led one of the controversial studies. But Fouchier already has an idea of what kinds of studies he would like to do.

(April 15, 2014) Vials of deadly SARS virus 'go missing' in France

A distinguished French research institute is assuring the public there is no need for concern over the fact it has lost 2349 vials of the deadly SARS virus. Institut Pasteur released a statement on Sunday admitting that a routine inventory could not account for the missing vials.

(June 2014) Yoshihiro Kawaoka of the University of Wisconsin-Madison has genetically manipulated the 2009 strain of pandemic flu

in order for it to “escape” the control of the immune system’s neutralising antibodies. Lord May said he suspected the NIH supported the work because officials there were "incompetent" and believed the justifications that scientists told them. "This is work that shouldn't be done. It's as simple as that," he said.

Institute for Influenza Virus Research in Madison which was built specifically to house Professor Kawaoka’s laboratory, which has a level-3-agriculture category of biosafety: one below the top safety level for the most dangerous pathogens, such as Ebola virus. However, this study was done at the lower level-2 biosafety.

Marc Lipsitch, Professor of Epidemiology at the Harvard School of Public Health, said: ‘I am worried that this signals a growing trend to make “transmissible” novel viruses willy-nilly. This is a risky activity, even in the safest labs. ‘Scientists should not take such risks without strong evidence that the work could save lives, which this paper does not provide.’ Other scientists used stronger language. ‘If society understood what was going on,’ thundered Professor Simon Wain-Hobson, of the Virology Department at the Pasteur Institute in Paris, ‘they would say “What the F are you doing?”

(October 17, 2014) U.S. halts funding for new risky virus studies, calls for voluntary Moratorium on Gain-of-Function Research

The White House today stepped into an ongoing debate about controversial virus experiments with a startling announcement: It is halting all federal funding for so-called gain-of-function (GOF) studies that alter a pathogen to make it more transmissible or deadly so that experts can work out a U.S. government-wide policy for weighing the risks.

(November 16, 2015) Ralph S. Baric, an infectious-disease researcher at the University of North Carolina at Chapel Hill published a study of an engineered virus with the surface protein of the SHC014 coronavirus,

found in horseshoe bats in China, and the backbone of one that causes human-like severe acute respiratory syndrome (SARS) in mice. The hybrid virus could infect human airway cells and caused disease in mice, according to the team’s results, which were published in Nature Medicine. Baric’s study on the SHC014-chimeric coronavirus began before the (2014) moratorium was announced, and the NIH allowed it to proceed during a review process, which eventually led to the conclusion that the work did not fall under the new restrictions, Baric told Nature. But some researchers, like Wain-Hobson, disagree with that decision.

“I don’t think it’s wise or appropriate for us to create large risks that don’t already exist,” says David Relman,
a microbiologist at Stanford University. He thinks the government was right to include SARS and MERS in this moratorium, because they are so close to being pandemic viruses. “I’m quite delighted that great scientists like Ralph Baric are working on SARS and doing the work they are doing,” says Relman. “But there still are specific experiments that I think should cause everyone pause and potentially cause concern if conducted.” For SARS and MERS, he says, “the one thing that I would feel most concerned about doing is to give them that one missing trait, their means of transmitting easily between humans.”

(May 28, 2015) Inside America's secretive biolabs

Since 2003, the CDC has referred 79 labs for potential enforcement actions by the U.S. Department of Health and Human Services' Office of Inspector General. It has levied fines against 19 of them totaling more than $2.4 million, the CDC said in response to questions. Some are repeat offenders. Five labs have had "multiple referrals" for enforcement actions, the CDC said. Two labs have been kicked out of the program, and five labs have been suspended from doing any select agent research, the agency said. Which labs repeatedly failed to address safety problems? The CDC won't name names — not even for the two labs kicked out of the select agent program.
The CDC and its regulatory partners at the USDA say the 2002 bio terrorism law requires keeping this information secret.

(October 9, 2015) Antiviral compound effectively treated Ebola in monkeys

(GS-5374 - later named Remdesivir) A clinical trial of the compound, GS-5374, is currently being conducted by the company Gilead Sciences, which worked with the United States Army Medical Research Institute of Infectious Diseases, or USAMRIID, to develop it.

(March 15, 2016) UNC Epidemiology Study: New SARS-Like Virus May Be Nearly Ready to Infect Humans

A study led by researchers at the University of North Carolina at Chapel Hill found that a SARS-like virus
known as WIV1-CoV, which is found in horseshoe bats, could bind to the same receptors as SARS-CoV and replicate in human cells without the need for adaptation.

Thought to be a critical barrier, the results indicate that bat populations maintain SARS-like viruses poised to reemerge in humans. The research team worked with both full length and chimeric versions of WIV1-CoV. The virus readily and efficiently replicated in cultured human airway tissues, suggesting and ability to potentially jump directly to humans. While other adaptations may be required to produce an epidemic, several viral strains circulating in bat populations have already overcome the barrier of replication in human cells and suggest reemergence as a distinct possibility.

(May 2016) at the United Nations Headquarters in New York, the inaugural ID2020 summit brought together over 400 people to discuss how to provide digital identity to all

A defined Sustainable Development Goal to include 1.5bn people living without any form of recognized identification. Experts in blockchain and other cryptographic technology joined with representatives of technical standards bodies to identify how technology and other private sector expertise could achieve the goal.

In 2019, ID2020 started a new digital identity program in collaboration with the government of Bangladesh and vaccine alliance Gavi.Participants: Accenture, Microsoft, Avanade Inc, PricewaterhouseCoopers, and Cisco Systems Inc have contributed their "expertise" to ID2020.

(August 2016) A Blueprint for Digital Identity

The Role of Financial Institutions in Building Digital Identity, an Industry Project of the Financial Services Community Prepared in collaboration with Deloitte

Members of the Steering Committee:

-Bob Contri, Vice Chairman - Deloitte & Touche LLP
-David Craig, President, Risk and Financial - Thomson Reuters
-John Flint, Chief Executive Officer, Retail Banking and Wealth Management - HSBC
-Kim Hammond, Chief Operating Officer - Deutsche Bank
-Jason Harris, Chief Executive Officer, International Property and Casualty - XL Group
-Michael Harte, Chief Technology Officer and Chief Operations Officer - Barclays
-Axel Lehmann, Chief Operating Officer - UBS
-Anju Patwardhan, Chief Innovation Officer - Standard Chartered Bank
-David Puth, Chief Executive Officer - CLS Group
-William Sheedy, Global Executive, Corporate Strategy, M&A, Government Relations - Visa
-Dietter Wemmer, Chief Financial Officer - Allianz

Members of the Working Group:

-Tom Brown, Partner - Paul Hastings
-Lena Mass-Cresnik, PhD, Head of Innovation, Strategic Product Management - BlackRock
-Christof Edel, Global Head of Trading Strategy & Business Development - Thomson Reuters
-Rob Galaski, (Project Advisor) Head of Financial Services - Deloitte
-Dorothy Hillenius, Director of Corporate Strategy - ING
-Marc Lien, Director of Innovation and Digital Development - Lloyds Banking Group
-Matthew Levin, EVP and Head of Global Strategy - Aon
-Victor Matarranz, Director of Strategy & Chief of Staff to the CEO - Santander
-Neil Mumm, VP Corporate Strategy - Visa
-Max Neukirchen, Group Head of Strategy - JP Morgan Chase
-Christine O’Connell, Global Head of Strategy & Business Development - Thomson Reuters
-Robert Palatnick, Managing Director and Chief Technology Architect - DTCC
-Kosta Peric, Deputy Director Financial Services for the Poor - Bill and Melinda Gates Foundation
-Justin Pinkham, SVP and Group Head, Payments Innovation - MasterCard
-Bob Reany, SVP and Group Head, Identity Solutions - MasterCard
-Peter Rutland, Senior Managing Director - CVC Capital Partners
-Nicolas de Skowronski, Chief of Staff - Bank Julius Baer
-Huw Van Steenis, Managing Director and Head of Financial Services Research - Morgan Stanley
-Colin Teichholtz, Partner & Co-Head of Fixed Income Trading - Pine River Capital
-Fabien Vandenreydt, Head of Markets Management, Innotribe & the SWIFT Institute - SWIFT

There is no one-size-fits-all for identity. A global system for identity therefore initially requires the construction of discrete identity networks, and then the creation of rails between them. Creating a global solution for identity is a two-step process: the key to building a global system for digital identity is first building successful natural identity networks that address the unique needs and preferences of their user group and situation,
and then building connective tissue that creates interoperability between these systems.

1. Implementation: Configuring natural identity networks
-The configuration of natural identity networks will be guided by the decisions made against the primary and secondary dimensions of choice.

2. Interconnection: Building the rails for global identity
-Building the rails between natural identity systems will create global interconnection and interoperability.

Building identity as a two-step process enables identity systems to be built by narrowing the required stakeholders to groups that have similar needs and concerns, and therefore have relatively aligned incentives. It also ensures that these systems are tailored to the specific needs and wants of their user and stakeholder groups and will therefore gain the uptake that a top-down, one-size-fits-all system would not attain.

However, these solutions should also be built following a common framework that will ensure interoperability by defining the features, attributes and requirements of the identities that are exchanged in the system. This reinforces the need for individual identity systems to be built by entities such as financial institutions that have experience working together to define standards, and then building individual systems within these standards.
Implementing discrete digital identity systems that suit the unique needs and cultural factors of users in their own jurisdictions, and designing these systems around resilience, interoperability and interconnection, will allow a global blueprint for digital identity to emerge.

(Jannuary 4, 2017) CDC keeps secret its mishaps with deadly germs

CDC scientists apparently lost a box of deadly and highly-regulated influenza specimens and experienced multiple potential exposures involving viruses and bacteria, according to heavily-redacted laboratory incident reports obtained by USA TODAY

(June 28, 2017) New drug holds potential to defeat coronaviruses

Scientists at the UNC Gillings School of Global Public Health have confirmed that an experimental antiviral treatment prevents the development of SARS coronavirus (SARS-CoV) disease in mice. The drug, GS-5734(Remdesivir), also inhibits MERS-CoV and multiple other coronaviruses (CoV), suggesting that the treatment may inhibit all CoV.

To date, there are no approved therapies to treat any kind of CoV infection. GS-5734 (Remdesivir) is being developed through a unique public-private partnership between investigators at the University of North Carolina, Vanderbilt University’s School of Medicine and Gilead Sciences, Inc.

(July 10, 2017) The Pentagon Ponders the Threat of Synthetic Bioweapons

They point to 2014, when the federal government halted 18 studies on so-called “gain of function”
research that tinkered with viruses like MERS, SARS, and the flu to make them more likely to transmit in humans. The [Trump] White House is taking another look at that moratorium to determine whether it still makes sense. Many scientists hope the ban is lifted—they argue understanding how viruses mutate is critical to stop them.

(August 31, 2017) Gillings School researchers receive $6M+ grant to fight infectious diseases

The partnership grant awarded to Baric and Sheahan establishes a collaboration between the Gillings School and Gilead Sciences Inc., Vanderbilt University Medical Center and the University of Texas Medical Branch. The collaboration builds upon an earlier partnership between the Gillings School and Gilead Sciences Inc., and will focus specifically on GS-5734 (Remdesivir), an experimental antiviral treatment.

(October 4, 2017) Broad-spectrum Investigational Agent GS-5734 (Remdesivir) for the Treatment of Ebola, MERS Coronavirus and Other Pathogenic Viral Infections with High Outbreak Potential

Antiviral activity of GS-5734 has been established in vitro against a wide range of pathogenic RNA virus families,
including filoviruses, coronaviruses, and paramyxoviruses.

(December 19, 2017) The US government is lifting a ban on engineering deadly viruses to make them more dangerous

More than 3 years after imposing a moratorium on U.S. funding for certain studies with dangerous viruses, the National Institutes of Health (NIH) in Bethesda, Maryland, today lifted this so-called "pause" and announced a new plan for reviewing such research. But federal officials haven’t yet decided the fate of a handful of studies on influenza and Middle East respiratory syndrome (MERS) that were put on hold in October 2014.

Many experts think the greatest possible threat to humanity is a fast-moving airborne pathogen — a particularly deadly flu virus could kill tens of millions of people in a year.

Notice Announcing the Removal of the Funding Pause for Gain-of-Function Research Projects:

(December 6, 2017) This New Blockchain Project Gives Homeless New Yorkers A Digital Identity

Three thousand homeless people in New York are about to receive a special holiday gift: a free smartphone that allows them to manage their digital identity, access shelters and food pantries, and make use of financial services. The initiative, which uses blockchain technology, may be the first time a distributed computer ledger has been employed to help a homeless population.

(January 24, 2018) US-China biotech startup XtalPi lands $15M from Google, Tencent and Sequoia

Google continues to increase its presence in China after it joined Sequoia China and Tencent in a $15 million investment for XtalPi, a U.S.-China biotech firm that uses artificial intelligence and computing to accelerate the development of new drugs. The search giant remains blocked in China, but that hasn’t stopped it from making a series of moves in recent months.

It is opening an AI lab in the country and now it has made a second significant investment in recent months by backing XtalPi, which was founded in 2014 by three Chinese MIT graduates. The company has 60 staff across offices in Cambridge, Beijing and Shenzhen.

It uses a combination of AI, quantum physics algorithms and cloud computing to predict the structure of drug molecules once they are crystalized, which in turn affects a drug’s stability and other characteristics that determine its chances of making it to market. Beyond its design focus — which makes the drug development process more efficient and accurate for pharma companies — XtalPi also works on drug discovery.

(January 24, 2018) Woman Working at NIH Killed in Parking Lot Crash

A woman working at the National Institutes of Health (NIH) died after she was hit by a vehicle Monday night in the campus' parking lot, the agency says.

Sang-A Park, a visiting post-doctoral fellow from South Korea, died after she was hit in the Bethesda, Maryland, parking lot about 5:30 p.m Monday., an NIH spokesman said in an statement. She was 27.

Just off the campus, a 35-year-old NIH employee, Francis G. Plati Jr., died in November 2015 after a motorcycle crash on Rockville Pike.

(February 12, 2018) Timothy Jerrell Cunningham (C.D.C. Employee) was last seen leaving work

and was a Harvard-educated (African American) doctor with the US Center for Disease Control and Prevention. As an epidemiologist, he was a team leader in the US Public Health Service Commissioned Corps and was named in 2017 as part of the Atlanta Business Chronicle's 40 Under 40 list. He also was the co-author of 28 publications on topics about sleep deprivation, pulmonary disease and more. Cunningham graduated from Morehouse and earned his S.M and ScD. from Harvard T.H. Chan School of Public Health

(March 6, 2018) What if billionaires could live forever?

Several billionaires, most of them Californians, have been funding firms involved in developing life-extension technologies. What if they succeed? What if billionaires alive today live indefinitely and get ever richer? Diamandis and Hariri's new venture is the latest example of a well-established phenomenon in Silicon Valley: Extremely wealthy techno-optimists have for years been funding biomedical R&D companies meant to achieve immortality for their funders. Some of the more recognizable names who have been putting money into such efforts: Larry Ellison (founder of Oracle), Larry Page and Sergey Brin (founders of Google), Jeff Bezos (founder of Amazon), and Peter Thiel, cofounder of PayPal and Palantir Technologies.

It does a lot of work for US government intelligence agencies. Thiel is a radical corporate libertarian, and Silicon Valley's best-known Donald Trump supporter. In late February, Diamandis wrote to subscribers of his email bulletin: "I asked the smartest people I know for their tech predictions for the next 20 years (2018 – 2038). What are the breakthroughs we can expect on our countdown to the Singularity?" One of the predictions he listed was that by 2030, "humanity will have achieved Longevity Escape Velocity for the wealthiest."

(April 10, 2018) HHS sponsors its largest exercise for moving patients with highly infectious diseases

The largest patient movement exercise in U.S. Department of Health and Human Services’ history began today to test the nationwide ability to move patients with highly infectious diseases safely and securely to regional treatment centers. 3qjVltQ

(April 13, 2018) Sanofi to Build $431M Vaccine Plant in Toronto

Sanofi plans to double its vaccine output by 2023 by building a €350 million ($431.5 million) vaccine manufacturing plant in Toronto. The project underscores the company’s reliance on vaccines as an engine for future growth despite more than $300 million in fourth-quarter charges tied to setbacks with two vaccines.

(May 10, 2018) Top White House official in charge of pandemic response exits abruptly

The top White House official responsible for leading the U.S. response in the event of a deadly pandemic has left the administration, and the global health security team he oversaw has been disbanded under a reorganization by national security adviser John Bolton. White House homeland security adviser Tom Bossert, who had called for a comprehensive biodefense strategy against pandemics and biological attacks, is out completely.

(June 11, 2018) Sanofi Pasteur, Translate Bio Launch mRNA Vaccine Partnership

Sanofi’s global vaccines unit Sanofi Pasteur will partner with Translate Bio to develop mRNA vaccines for up to five undisclosed infectious disease pathogens, through a collaboration that the mRNA therapeutics developer said today could generate for it up to $805 million-plus.

(July 8, 2018) Opposition to Breast-Feeding Resolution by U.S. Stuns World Health Officials

A resolution to encourage breast-feeding was expected to be approved quickly and easily by the hundreds of government delegates who gathered this spring in Geneva for the United Nations-affiliated World Health Assembly. Then the United States delegation, embracing the interests of infant formula manufacturers, upended the deliberations. Ecuador, which had planned to introduce the measure, was the first to find itself in the cross hairs.The Americans were blunt: If Ecuador refused to drop the resolution, Washington would unleash punishing trade measures and withdraw crucial military aid. The Ecuadorean government quickly acquiesced.

(August 3, 2018) China culls 900 pigs after reports of first African swine fever outbreak in country

China has reported its first case of African swine fever (ASF), a highly contagious disease of pigs,
in the northeastern city of Shenyang and culled more than 900 hogs to prevent the epidemic from spreading,
local media reported. This is also the first reported case in East Asia.

(September 29, 2018) Vaccitech licenses MERS rights to Oxford University

Vaccitech licenses MERS rights to Oxford University CEPI (the Coalition for Epidemic Preparedness Innovations) today announced a collaboration with The Jenner Institute at the University of Oxford and Lanssen Vaccines & Prevention B.V.—part of the Janssen Pharmaceutical Companies of Johnson & Johnson
—through which they will receive funding to advance the development and manufacture of a vaccine against Middle East Respiratory Syndrome Coronavirus (MERS-CoV).

Oxford has already initiated clinical development of the MERS-CoV vaccine, with funding from the UK Department of Health and Social Care, and a phase 1 clinical trial of the vaccine is underway in the UK. Under the terms of the Framework Partnering Agreement for the collaboration, Oxford and Janssen will receive $14.6 million from CEPI
to support manufacturing of a phase 2 batch and preparation for stockpiling of a MERS-CoV vaccine candidate.
Oxford will undertake phase 2 testing of the vaccine, in partnership with the King Abdullah International Medical Research Centre (KAIMRC) in Riyadh, Kingdom of Saudi Arabia, and the Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme at Kilifi, Kenya.

(October 30, 2018) J&J unveils new vaccines facility in Leiden, Netherlands

Johnson & Johnson has unveiled a new vaccines facility in Leiden, the Netherlands, to support the development and roll out of new vaccines on a mass scale for public use globally. Built by Janssen Vaccines & Prevention, the centre contains new technological and manufacturing platforms to aid large-scale manufacturing of Janssen vaccines for use in late-stage clinical trials.

Janssen is currently developing investigational vaccines for multiple infectious diseases such as HIV, respiratory syncytial virus (RSV), influenza, Ebola and Zika. The vaccines launch facility can also support the company’s efforts for global pandemic preparedness, including the development of a new Middle East respiratory syndrome (MERS) vaccine in alliance with the Coalition for Epidemic Preparedness Innovations (CEPI).

(December 6, 2018) Mastercard and Microsoft have a frightening plan to create universal “digital identities”

The companies are building a solution that would create a “universally-recognized digital identity.” To the corporations, this is a brilliant solution! To everyone else, it may feel more than a bit dystopian. What this announcement seems to be describing is a streamlined identification system: a not-too-far-off world where people are identified under a universal protocol that checks in on them at various points during their lives–when they vote, when they get married, etc. It’s the kind of a citizen-check system a totalitarian regime could only dream of.

Last edited by Kerstin on Sun Feb 14, 2021 3:26 am; edited 1 time in total

Posts : 85
Join date : 2020-09-18

Back to top Go down

THE COVID-19 TIMELINE 1980 - 2020 Empty Re: THE COVID-19 TIMELINE 1980 - 2020

Post by Kerstin Sat Feb 13, 2021 10:35 pm


(February 27, 2019) CEPI, CureVac team up in $34M deal to advance RNA vaccine 'printer'

Since it formed two years ago, the global outbreak preparedness group CEPI has invested hundreds of millions of dollars in vaccine candidates against infectious diseases. Now, it’s back at it with CureVac in a deal to help the biotech advance its mRNA vaccine "printer." After preclinical work, the partners aim to advance two vaccine candidates against named diseases into phase 1 testing. Along the way, CureVac will continue collaborating with its existing partners, including the University of Wisconsin. CEPI’s grant to CureVac is one in a series of investments the global preparedness group has made. Formed in 2017, the group initially focused on Lassa, MERS and Nipah viruses, but more recently has sought partners to work on vaccine platforms against unknown pathogens,
plus Rift Valley fever virus and Chikungunya.

(January - August 2019) Crimson Contagion simulation

Crimson. Contagion simulation was a simulation administered by Trump's U.S. Department of Health and Human Services from January to August 2019 that tested the capacity of the U.S. federal government and twelve U.S. states to respond to a severe influenza pandemic originating in China.

The exercise involves a scenario in which tourists returning from China spread a respiratory virus in the United States, beginning in Chicago. In less than two months the virus had infected 110 million Americans, killing more than half a million. The report issued at the conclusion of the exercise outlines the government's limited capacity to respond to a pandemic, with federal agencies lacking the funds, coordination, and resources to facilitate an effective response to the virus.

(March 1, 2019) Studies of Deadly Flu Virus, Once Banned, Are Set to Resume

The government will allow research on bird flu that had been halted over safety concerns. But officials have not publicly announced the decision nor explained how it was made.

(June 11, 2019) Tweets from Turkish psychic-insider close to authorities

"The U.S. sent an aircraft of biological weapons to China. Epidemics may begin in China soon.
They should not forget that if there is a Turk on earth, there is hope."

THE COVID-19 TIMELINE 1980 - 2020 Screen84

(June 19, 2019) Sanofi, Google Launch “Innovation Lab” Aimed at Drug Discovery

Sanofi will apply Google’s artificial intelligence (AI) and cloud computing capabilities toward developing new drugs, through a collaboration whose value was not disclosed. The companies said they have agreed to create a virtual Innovation Lab to “radically” transform how future medicines and health services are developed and delivered.

(July 17, 2019) Cause of Respiratory Illness Still Unknown After Dozens Sickened at Virginia Retirement Community

Fairfax County health officials said they don't yet have a cause of the respiratory illness that sicked more than 60 residentsat a Northern Virginia senior living community. The outbreak at Greenspring Retirement Community in Springfield began June 30. Sick residents had symptoms such as coughs, fevers and pneumonia.

(July 17, 2019) Second Fairfax County retirement community suffers respiratory illness outbreak

The Fairfax County Health Department in a press conference included information regarding Greenspring Retirement Community and another long-term care facility, Heatherwood, in Burke. “Of the outbreaks that are not flu, there are somewhere we never identify [them],” Schwartz said. “It’s just difficult to do the testing and to identify the cause in older adults.”

(July 17, 2019) Third person has died after respiratory illness outbreak at Greenspring Village, Fairfax officials say

A third person has died following an outbreak of respiratory illness at a Fairfax County assisted-living facility that began more than two weeks ago, county health officials said Wednesday. The outbreak at Greenspring Village in Springfield also spread to the unit’s staff, affecting 19 employees, Fairfax County Health Department officials said.

At a news conference Wednesday at the agency’s headquarters, Benjamin Schwartz, director of epidemiology and population health at the Fairfax County Health Department, said tests, including those conducted on 17 samples by the federal Centers for Disease Control and Prevention, have failed to identify a likely cause. Tests for Legionnaires’ disease have also come up negative. Officials tested for a range of common virus- or bacteria-borne respiratory illnesses.

THE COVID-19 TIMELINE 1980 - 2020 Screen85

(July 2019) Fort Detrick lab shut down after failed safety inspection; all research halted indefinitely

Premise: Hon Lik (or Han Li) a Chinese native, born in Shenyang, China registered a patent for the modern e-cigarette design in 2003. The e-cigarette was first introduced to the Chinese domestic market in 2004., entered the European market and the US market in 2006 and 2007. In the UK, users have increased from 700,000 in 2012 to 2.6 million in 2015, and in 2015 around 10% of American adults were users. About 60% of UK users are smokers and about 40% are ex-smokers, while use among never-smokers in the UK is negligible.

(July 29, 2019) Eight Milwaukee-area teens hospitalized with severe lung damage that may have been caused by vaping

The teens were brought to Children's Hospital of Wisconsin with extreme cough, significant shortness of breath and fatigue. Some had lost weight from vomiting and diarrhea, hospital officials said Thursday.

(August 17, 2019) Mystery lung illness linked to vaping. Health officials investigating nearly 100 possible cases.

In the past month, the teenagers presented symptoms that appeared manageable and consistent with viral-type infections or bacterial pneumonia — shortness of breath, coughing, fever and abdominal discomfort, Chapman said. But they continued to deteriorate despite appropriate treatment, including with antibiotics and oxygen support. Some suffered respiratory failure and had to be put on ventilators, she said.

(August 22, 2019) Merck teams up with Themis to develop vaccines

Merck has struck a deal to work with Themis Bioscience on vaccine R&D. The agreement sees Merck invest in Themis and commit up to $200 million (€180 million) in milestones to secure vaccines against an undisclosed target. Using research funding from Merck, Themis will develop vaccine candidates against the target using its measles virus vector-based platform. Themis licensed the measles vector from the Pasteur Institute and has since worked to industrialize the production process, giving it a platform it thinks can support an upcoming phase 3 trial of its internal lead asset. The result is a setup Themis CEO Erich Tauber describes as a “true plug-and-play platform.” The progress of Themis’ internal programs and its work with the Coalition for Epidemic Preparedness Innovations (CEPI) have provided evidence of the company’s success in building on the licensed vector.

(September 9, 2019) Respiratory Disease Outbreak Summary

The initial findings from the investigation revealed that the respiratory illness cases were clustered in an Assisted Living and Skilled Nursing facility. Cases diagnosed as pneumonia generally required hospitalization. Affected residents were very elderly with underlying medical conditions. All testing at Inova Central Lab was negative for etiology, and no severe illness in Independent Living or among staff occurred.

Dr. Schwartz reviewed each step in the investigation, which included maps and floor plans of confirmed cases. At the conclusion of the outbreak, there were 63 cases and 7 deaths. Among the fatalities, it is not clear how pneumonia may have contributed to infection as most residents had other health conditions.

(September 12, 2019) Europe’s missing ‘vaping sickness’

Europe does not appear to be experiencing an outbreak of the “vaping sickness” gripping the U.S. It’s not clear anyone would know if it was. U.S. President Donald Trump on Wednesday moved to finalize a ban on flavored e-cigarettes in light of the country’s outbreak of a vaping-related illness that’s made 450 people sick and resulted in at least six deaths.

“We have not seen anything like what we’ve seen in the U.S. recently in Europe, to my knowledge as a scientist, and I’m pretty aware of the field,” said Constantine Vardavas, the European Respiratory Society’s scientific relations director with the EU.

(September 27, 2019) Flu season threatens to complicate diagnoses of vaping-related illness

The issue, experts say, is that flu and other respiratory viruses can, in many ways, look strikingly similar to a case of vaping-related illness: Symptoms include shortness of breath, night sweats, low oxygen levels, and hazy spots on a lung X-ray.

“It’s going to be difficult to tease apart a bad flu case and a vaping case,” said Dr. Sean Callahan, a University of Utah Health pulmonologist who has treated several cases of vaping-related illness. The CDC, when asked, didn’t respond directly to the question of whether its definition might need to be revised.

(September 2019) Trump administration cut pandemic early warning program

The Trump administration decided to end a $200m early warning program designed to alert it to potential pandemics just three months before it is believed Covid-19 began infecting people in China.

The project, called Predict, had been run by the US Agency for International Development since 2009. It had identified more than 160 different coronaviruses that had the potential to develop into pandemics, including a virus that is considered the closest known relative to Covid-19.

(September 2019) Bill Gates made a Netflix video

which made an eerie imaginary scenario. The video, part of the “Explained” series, imagined a wet market in China where live and dead animals are stacked and a highly deadly virus erupts that spreads globally.

Bill Gates appears as an expert in the video to warn “If you think of anything that could come along that would kill millions of people, a pandemic is our greatest risk” threatening if nothing was done to better prepare for pandemics, the time would come when the world would look back and wish it had invested more into potential vaccines.

(October 4, 2019) US vaping illness deaths rise to 18 with 1,000 cases reported

At least 18 deaths and more than 1,000 cases of a mysterious lung illness have been linked with vaping by US health authorities. Doctors have been unable to establish what is causing the illness, whose symptoms include chest pain, fatigue and shortness of breath.

(October 3, 2019) Conservative groups urge Trump to back off ban on flavored vaping products

The Food and Drug Administration (FDA) is expected to issued guidance on the prohibition soon, arguing the flavors are appealing to children and leading to rising youth vaping rates. But conservatives say the ban, which doesn't apply to tobacco flavors, would hurt small vape businesses and adults trying to quit cigarettes.

(October 18, 2019) Event 201 - global pandemic exercise

Event 201 was a large scale simulation of a global coronavirus pandemic. The final presentation was held in front of an audience on 18 October 2019. The "exercise players" were prominent individuals from global business, government, and public health, including Avril Haines, who was Deputy Director of the CIA under Obama.The Johns Hopkins Center for Health Security in partnership with the World Economic Forumand the Bill and Melinda Gates Foundation hosted Event 201.

Last edited by Kerstin on Sun Feb 14, 2021 3:37 am; edited 3 times in total

Posts : 85
Join date : 2020-09-18

Back to top Go down

THE COVID-19 TIMELINE 1980 - 2020 Empty Re: THE COVID-19 TIMELINE 1980 - 2020

Post by Kerstin Sat Feb 13, 2021 11:01 pm


(October 16, 2019) the 7th CISM Military World Games held in Wuhan

Five foreign athletes from military world games in Wuhan infected with malaria, not COVID-19 in October 2019, says hospital head.

(October 25, 2019) Scientists Were Hunting for the Next Ebola. Now the U.S. Has Cut Off Their Funding

In a move that worries many public health experts, the federal government is quietly shutting down a surveillance program for dangerous animal viruses that someday may infect humans.

(November 15, 2019) CDC begin hiring Quarantine Public Health Advisors

Location: Anchorage, Alaska, Los Angeles, California, San Diego, California, San Francisco, California,
Miami, Florida, Atlanta, Georgia, Honolulu, Hawaii, Chicago, Illinois, Boston, Massachusetts, Detroit, Michigan,
Minneapolis, Minnesota, Newark, New Jersey, New York, New York, Philadelphia, Pennsylvania, Dallas, Texas, El Paso, Texas, Houston, Texas, Seattle, Washington, San Juan

Deleted original CDC link:

THE COVID-19 TIMELINE 1980 - 2020 Ewake710

(November 17, 2019) U.S. and South Korea postpone military drills in bid to save North Korea dialogue

The United States and South Korea have postponed joint air drills that were scheduled this month in an attempt
to save a faltering dialogue process with North Korea, officials announced Sunday.

(November 23, 2019) CDC Approves Partial Resumption of USAMRIID Select Agent Research

The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) will resume limited research, following a successful recent inspection by the Centers for Disease Control (CDC) and Prevention.

(November 23, 2019) ‘Not enough pork in the world’ to deal with China’s demand for meat

With hundreds of millions of pigs dead from swine fever, exporters are scrambling to fill the gap. But prices are soaring. The cost of living in China has outstripped the 3% government target for the first time in a decade,
and a big part of the problem is the soaring price of pork, which is being driven up by a widespread outbreak of African swine fever (ASF).

(December 19, 2019) Quantum Dots Deliver Vaccines and Invisibly Encode Vaccination History in Skin

Researchers headed by a team at the Massachusetts Institute of Technology (MIT) have created a microneedle platform using fluorescent microparticles called quantum dots (QD), which can deliver vaccines and at the same time invisibly encode vaccination history directly in the skin. The quantum dots are composed of nanocrystals, which emit near-infrared (NIR) light that can be detected
by a specially equipped smartphone

(December 12, 2019) Australia, Canada look to digital identity solutions to get rid of physical ID cards

Mastercard has rolled out a new digital identity pilot in Australia this week that can identify a person in both digital and physical environments, the company announced. Mastercard is testing different ways of proving identity without having to rely on multiple physical documents or centralized identity databases. The project is based on a distributed model that, when activated, uses information from the mobile device which has been checked through additional reference points, such as the person’s bank or government agencies
taking part in the pilot.

The pilot program is carried out in partnership with Australia Post which will use the existing digital ID solution to enable Australians to identify themselves when using the services, and with Deakin University where student volunteers will test an identity verification process for student registration and digital exams.

Canadian province Quebec is also looking into biometrics to confirm online identity and get rid of traditional physical government IDs by 2021, writes CBC. The government is waiting to see if any companies in the private sector would be interested in taking over the project. Details about cost have not been revealed.

Exclusive: U.S. Axed CDC Expert Job in China Months Before Virus Outbreak
NYT link deleted:


Posts : 85
Join date : 2020-09-18

Back to top Go down

THE COVID-19 TIMELINE 1980 - 2020 Empty Re: THE COVID-19 TIMELINE 1980 - 2020

Post by Kerstin Sun Feb 14, 2021 12:11 am


(January 30, 2020) Johnson & Johnson to develop coronavirus vaccine

Johnson & Johnson announced that it has begun development of a vaccine for the novel Coronavirus outbreak through its subsidiary, Janssen Pharmaceutical Companies. “This latest outbreak of a novel pathogen once again reinforces the importance of investing in preparedness, surveillance and response to ensure the world remains ahead of potential pandemic threats,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson. The vaccine program will leverage Janssen’s AdVac and PER.C6 technologies that provide the ability to rapidly upscale production of the optimal vaccine candidate. These are the same technologies that were used in the development and manufacturing of Janssen’s investigational Ebola vaccine, which is currently deployed in the Democratic Republic of the Congo and Rwanda. They were also used to construct the Company’s Zika, RSV and HIV vaccine candidates.

The PER.C6 cell line is derived from human embryonic retinal cells, originally from the retinal tissue of an 18 week old fetus aborted in 1985 and further developed and prepared as cell line by transfection with defined E1 region of the adenovirus type 5 followed by selection for transfectants with an immortal phenotype.

[Note:"immortalized cell lines" is a fancy medical word for their synthesized Frankenstein cancer cells production]

(March 19, 2020) Trump administration ran pandemic simulation months before coronavirus hit

Former Air Force physician Robert Kadlec, who has studied biodefense issues for decades, led the exercise, which imagined a contagious disease that originated in China and spread globally after nearly three dozen tourists were infected and returned home. The hypothetical outbreak spread quickly through the U.S. after an infected person attended a concert packed with thousands of others. The exercise, which took place from January to August of last year, highlighted some of the problems that the federal government is struggling to handle now, such as insufficient hospital space and medical supplies, as well as confusion between federal agencies and between states and the federal government.

(March 24, 2020) Gilead’s potential coronavirus treatment gets FDA’s orphan drug label

Gilead Sciences’ experimental drug Remdesivir, seen as one of the more promising potential treatments for the coronavirus, on Monday received the orphan drug designation from the U.S. Food and Drug Administration.
The orphan drug status provides a seven-year market exclusivity period, as well as tax and other incentives for drug companies developing treatments for rare diseases that affect fewer than 200,000 people.

(May 1, 2020) UK government invited Google DeepMind exec to critical coronavirus meeting

The U.K. government invited DeepMind co-founder and CEO Demis Hassabis to attend a meeting of the scientific advisory group for emergencies (Sage) on March 18, around the time officials were considering a lockdown. His attendance, reported by The Guardian, has got people asking questions. Namely, what was the leader of an American-owned AI firm doing at a top-secret government meeting on the coronavirus?

(May 1, 2020) Vaccine Leader Signs Deal for 1 Billion Covid-19 Doses a Year

Moderna Inc., one of the leaders among U.S. companies developing experimental vaccines against the coronavirus, entered a pact with Lonza Group AG aimed at manufacturing 1 billion doses a year. The companies announced a global agreement under which the Swiss chemical and pharmaceutical company will ramp up output of the proposed vaccine, which is based on a novel technology that relies on genetic material called mRNA. They expect the first batches to be produced in the U.S. in July.

[Note: Moderna's mRNA is not "genetic material", it is synthetic and was designed on a computer. Moderna's official website says their synthetic mRNA injection is an (OP) Operating System, and dubbed it the "SOFTWARE OF LIFE"

THE COVID-19 TIMELINE 1980 - 2020 Screen86

(May 5, 2020) 15 Children Are Hospitalized With Mysterious Illness Possibly Tied to Covid-19

Fifteen children, many of whom had the coronavirus, have recently been hospitalized in New York City with a mysterious syndrome that doctors do not yet fully understand but that has also been reported in several European countries, health officials announced on Monday night. Many of the children, ages 2 to 15, have shown symptoms associated with toxic shock or Kawasaki disease, a rare illness in children that involves inflammation of the blood vessels, including coronary arteries, the city’s health department said.

[Note: may be related to African Swine Flu (ASF) which I've dubbed "Pig Ebola", symptoms in pigs are very similar to the symptoms in children.]

(May 5, 2020) Amid Ongoing COVID-19 Pandemic, Governor Cuomo Announces Collaboration with Gates Foundation to Develop a Blueprint to Reimagine Education in the New Normal

"One of the areas we can really learn from is education because the old model of our education system where everyone sits in a classroom is not going to work in the new normal. When we do reopen our schools let's reimagine them for the future, and to do that we are collaborating with the Bill & Melinda Gates Foundation and exploring smart, innovative education alternatives using all the new technology we have at our disposal."

(May 6, 2020) New York Gov. Cuomo just tapped former Google CEO Eric Schmidt to help invent a more tech-focused future for the state post-pandemic

"The first priorities of what we're trying to do are focused on telehealth, remote learning and broadband,"
said Eric Schmidt, who dialed in by video conference. "We can take this terrible disaster and accelerate
all of those in ways that will make things much, much better." Schmidt said the pandemic has provided the state with an opportunity to update old and neglected systems and develop new ways to do things, and stressed that the commission's "intent is to be very inclusive" in its approach. Schmidt is the third billionaire Cuomo has tapped in recent weeks to advise New York on post-pandemic changes.

(May 6, 2020) Gilead Outlines Efforts to Expand Global Supply of Remdesivir for COVID-19

Gilead Sciences’ antiviral drug Remdesivir is, to date, the only approved drug treatment for COVID-19. Shortly after announcing positive results in two clinical trials on April 30, one a small trial run by the company, the other a larger trial conducted by the National Institutes of Allergy & Infectious Diseases (NIAID), the U.S. Food and Drug Administration (FDA) approved the drug under Emergency Use Authorization (EUA) for COVID-19.
Gilead is in talks with chemical and pharmaceutical manufacturing companies around the world to work out voluntary licenses to produce remdesivir for Europe, Asia and the developing world through at least 2022.

[Note: an EUA is not even close to the regular drug approval process, they need the EUA because they cover up the fact that none of these medical products meet the standard definition of vaccines, and since they cannot approve "experimental gene therapy"/injectable chemo therapy they use the WHO declared pandemic as a convenient cover]

(May 6, 2020) COVID RIDDLE Fears coronavirus arrived in Europe in OCTOBER ‘when French athletes at World Military Games in Wuhan brought it home’

Elodie Clouvel, a world champion modern pentathlete, was asked on local TV station Television Loire 7 on March 25 if she was worried about the prospect of potentially having to spend the summer in Japan for the Olympics. She replied: "No because I think that with Velentin [Belaud, her partner, also a pentathlete] we have already had the coronavirus, well the Covid-19."

(May 7, 2020) Computational Biologist Bing Liu Dies in Suspected Murder

Bing Liu, a computational systems biologist at the University of Pittsburgh who was studying the virus that causes COVID-19, was shot to death in his home on May 2. He was 37 years old. Liu had been studying the infection mechanism of SARS-CoV-2. According to the department’s statement,
Bing was on the verge of making very significant findings toward understanding the cellular mechanisms that underlie SARS-CoV-2 infection and the cellular basis of the following complications.

Last edited by Kerstin on Sun Feb 14, 2021 3:54 am; edited 3 times in total

Posts : 85
Join date : 2020-09-18

Back to top Go down

THE COVID-19 TIMELINE 1980 - 2020 Empty Re: THE COVID-19 TIMELINE 1980 - 2020

Post by Kerstin Sun Feb 14, 2021 12:59 am


(May 7, 2020) "In October in Wuhan we all got sick": the swordsman Tagliarol was in China at the military World Cup

At the Wuhan military world championship "we all got sick, 6 out of 6 in the apartment and a lot of other delegations. So much so that the medical center had almost run out of medicine". "I had a fever and cough for 3 weeks - says the blue swordsman - and the antibiotics did nothing; then it was my son and my partner's turn. I'm not a doctor, but the symptoms seem to be those of Covid-19.

(May 8, 2020) U.S. mayor suspects he caught coronavirus in November 2019

The mayor of a U.S. city in the state of New Jersey claims he recently tested positive for COVID-19 antibodies and suspects he was infected by the virus in November, about two months before the first confirmed case in the country. However, amid the coronavirus virus pandemic, questions have been raised about the reliability of antibody tests and the ability to pinpoint the exact time of infection. And it's not clear whether anyone else who had contact with the mayor contracted the virus.

(May 08, 2020) Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities

As the cases of coronavirus disease 2019 (COVID-19) continue to increase across the world, evidence is continuing to emerge that the pandemic could be disproportionately affecting people from black, Asian, and minority ethnic (BAME) communities. In the UK, this trend first came to public attention during media reports that showed the first 11 doctors who sadly lost their lives to COVID-19, were all from BAME communities.

(May 11, 2020) Novavax scores $384M deal, CEPI's largest ever, to fund coronavirus vaccine work

After winning a small grant for early vaccine work in March, Novavax just won the largest-ever investment from CEPI, a global coalition aiding COVID-19 vaccine development. The grant of up to $384 million from the Coalition for Epidemic Preparedness Innovations will fund Novavax’s COVID-19 vaccine testing through phase 2, plus early work to scale-up manufacturing. The funding follows a $4 million award back in March. The Maryland biotech will use the funds to conduct a phase 1/2 trial on its candidate, NVX-COV2373, starting with the phase 1 portion in Australia this month. Beyond testing, the company intends to use part of the funds to scale up production to make up to 100 million doses by the end of 2020. The company aims to make more than 1 billion doses in 2021.

Novavax's COVID-19 candidate is a recombinant nanoparticle vaccine combined with the company's Matrix-M adjuvant. The platform recently succeeded in a phase 3 trial for NanoFlu,a quadrivalent influenza shot, in adults 65 and older.

(May 15, 2020) Overnight Health Care: Trump touts accelerated push on vaccines

President Trump formally introduced the new head of his "Operation Warp Speed," a public-private partnership to push for a vaccine to prevent COVID-19.There are a couple of new faces in the administration’s coronavirus response efforts: Former pharmaceutical executive Moncef Slaoui and Army Gen. Gustave Perna are heading up the Operation Warp Speed vaccine development effort. Slaoui will serve as the project's chief scientist while Perna will serve as its chief operation officer.

(May 17, 2020) Government to invest £93m in UK vaccine manufacturing centre

The British government will invest up to £93m to bring forward construction of a new vaccine manufacturing centre,
the Department for Business, Energy and Industrial Strategy said on Saturday. The funding will ensure the new centre opens in summer 2021, a year ahead of schedule. The Vaccines Manufacturing and Innovation Centre (VMIC) is a key component of the government’s programme to ensure that once a coronavirus vaccine is available, it can be rolled out quickly in mass quantities, the department said. The not-for-profit facility on the Harwell science and innovation campus in Oxfordshire will have the capacity to produce enough doses for the entire UK population in as little as six months.

(May 20, 2020) Trump’s Vaccine Chief Has Vast Ties to Drug Industry, Posing Possible Conflicts

The scientist, Moncef Slaoui, is a venture capitalist and a former longtime executive at GlaxoSmithKline. Most recently, he sat on the board of Moderna, a Cambridge, Mass., biotechnology firm with a $30 billion valuation that is pursuing a coronavirus vaccine. He still holds just under $10 million in GlaxoSmithKline stock and remains a partner in Medicxi, a venture capital firm that specializes in investing in biotech concerns, with several companies engaged in the global race to develop treatments or vaccines to stanch the coronavirus pandemic. GSK and Sanofi have become partners in creating a vaccine candidate against the coronavirus.

(May 20, 2020) This Startup's Covid-19 Test Would Give Results in 20 Minutes
San Francisco-based startup Mammoth Biosciences is developing an at-home test for SARS-CoV-2, the virus that causes Covid-19. The test can determine in 20 minutes whether someone is carrying the virus, thanks in part to the gene-editing technique known as Crispr, according to Mammoth. Mammoth's test requires the user to take a nasal swab or spit into a vial; a color indicator then reveals a positive or negative result.

The startup is partnering with London-based pharmaceutical giant GlaxoSmithKline to bring the test to market. Mammoth has $68 million in funding from investors including Mayfield Fund, Verily, NFX, and Brook Byers.

(May 21, 2020) U.S. Raises Ante in Vaccine Race With $1.2 Billion for AstraZeneca

The U.S. threw its weight behind one of the fastest-moving experimental solutions to the coronavirus pandemic, pledging as much as $1.2 billion to AstraZeneca Plc to help make the University of Oxford’s Covid vaccine. The U.K. drugmaker received the money from the U.S. Biomedical Advanced Research and Development Authority (BARDA)
and said it has secured capacity to make 1 billion doses. Astra has identified supply chains in the U.S. and U.K., according to Soriot. Soriot said Astra is working with groups including the World Health Organization, the Coalition for Epidemic Preparedness Innovations(CEPI) and Gavi, the Vaccine Alliance, on making sure the vaccine is allocated fairly so that poorer countries have access. The company has supply agreements for 400 million doses.

(May 22, 2020) Immunity Passports and the Perils of Conferring Coronavirus Status

Recently, Onfido submitted a proposal to members of the U.K. Parliament’s science and technology committee, as they consider ways to lift stay-at-home orders, including the development of immunity passports. COVI-Pass is an immunity passport that uses VCode—a proprietary cryptographic image, similar to a QR code—that can be scanned at a distance of a hundred metres. It will reveal if a person has tested positive for antibodies, flash green if a person has tested negative for the virus, and red if tests show that they have the virus or don’t have antibodies, or if their test result has expired. (A yellow light shows when it’s time to be retested.) The app can “geo-fence” a point of entry, prohibiting visitors with a red light from entering a building or stadium or school.

“I believe that all governments will move toward a global health passport, which will be as common as carrying a driver’s license or a passport, because this is not going to be the last pandemic we have,” Adam Palmer, the C.O.O. of COVI-Pass, said.

[Note: how does he know that there will be other pandemic any time soon? Is he a Prophet like Bill Gates?]

(May 25, 2020) Swiss tracing app goes on trial

Switzerland is the first country in the world to use APIs from Google and Apple. The app is being developed as part of the DP-3T project by ETH Zurich and EPF Lausanne, working together with international researchers. ETH scientists are actively involved in the design, security assessment, data protection and performance of the SwissCovid app. Srdjan Capkun, Professor for Systems and Network Security, one of the developers of the SwissCovid app, stresses: "This is not 'only' a smartphone app, but a complex distributed contact tracing system.

(May 26, 2020) Merck inks Themis buyout to join COVID-19 vaccine race

Merck has struck a deal to buy Themis to accelerate the development of a COVID-19 vaccine. The takeover will see Merck, a latecomer to the response to SARS-CoV-2, apply its vaccine capabilities to a candidate based on Themis’ measles vector platform that is set to enter the clinic this year. Themis is developing a pipeline of vaccines based on a measles virus vector platform it licensed from Institut Pasteur. “Together with Institut Pasteur, we have worked on very closely related viruses like SARS and MERS and demonstrated the platform is very useful in eliciting an immune response,” Themis CEO Erich Tauber said. “We started [SARS-CoV-2] vector design in February. We have started in vivo models ... and are now preparing for clinical trials.” Merck is now set to apply its vaccine capabilities to the program.

The Big Pharma has a major human vaccine operation, which generated sales of $8.4 billion last year,
but it stayed on the sidelines in the early days of the pandemic as peers such as AstraZeneca, Pfizer and Sanofi placed bets on COVID-19 vaccine candidates.

(May 27, 2020) Novavax snares $167M buyout to rapidly scale up COVID-19 vaccine manufacturing

Novavax will fork over $167 million for Czech manufacturer Praha Vaccines and team up with vaccine giant Serum Institute of India in moves that will add capacity for 1 billion-plus doses per year of a potential COVID-19 shot, the drugmaker said Wednesday. As part of the acquisition, Maryland-based Novavax will pick up Praha's 150,000-square-foot, 150-employee facility in Bohumil, Czech Republic. The "state-of-the-art " plant is undergoing renovation and is outfitted for vaccine and biologics manufacturing. The Praha buyout, funded with a $384 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI), will bring Novavax's vaccine manufacturing capacity above 1 billion doses by 2021.

(May 28, 2020) AstraZeneca locks up COVID-19 vaccine supply with Oxford BioMedica production deal

AstraZeneca is on the hook for millions of doses of the University of Oxford's front-runner COVID-19 vaccine candidate, assuming it proves effective. To fill those orders, the British drugmaker has agreed to a short-term manufacturing deal that will help it bridge the gap. AstraZeneca and Oxford BioMedica inked a one-year deal covering "multiple batches" of the University of Oxford's adenovirus-based COVID-19 vaccine candidate, AZD1222 (ChAdOx1 nCoV-19), as part of a consortium aimed at speeding production of the shot. The vaccine, developed by the University of Oxford’s Jenner Institute, contains the genetic material of the SARS-CoV-2 spike protein.

[Note: it's called ChAdOx1 "recombinant" for a reason, it means that it contains genetically modified (GMO) monkey DNA]


Posts : 85
Join date : 2020-09-18

Back to top Go down

THE COVID-19 TIMELINE 1980 - 2020 Empty Re: THE COVID-19 TIMELINE 1980 - 2020

Post by Kerstin Sun Feb 14, 2021 2:04 am


(May 28, 2020) Advisor resigns from ID2020 objecting to blockchain immunity passports for COVID-19

Elizabeth M. Renieris, a Harvard lawyer on the ID2020 technical advisory committee, has resigned from the ID2020 Alliance. Renieris’ resignation was driven by concerns that the organization will get involved in COVID-19 immunity passports, as Coindesk first reported. The ID2020 Alliance was founded by Accenture, Microsoft, Gavi, Rockefeller Foundation and IDEO. Partners include Mastercard, which joined last week, as well as NGOs and UN agencies. Renieris believes immunity passports could potentially infringe privacy rights for tests that are unproven and that the identity and blockchain standards are still a work in progress.

(June 3, 2020) Portable digital identity solution with face biometrics successfully exits FCA regulatory sandbox

A reusable digital identity solution leveraging face biometrics and developed by Onfido, Deloitte, and Evernym has successfully exited a regulatory sandbox pilot with the UK’s Financial Conduct Authority (FCA), which the company’s say shows that portable digital ID is now market-ready. “Now that we’ve proven the model in one of the toughest regulated markets in the world, we’re rapidly proceeding to apply it to other geographies and services as well such as renting a car, self-checking into a hotel and one day, even voting.” “When you put the individual in charge of her digital identity, everyone wins. It gives consumers the freedom to securely move about the digital world, and businesses the ability to finally know and trust who they are interacting with.”

[Note: sure, "customers" can't wait for the implementation of surveillance capitalism, because it is so convenient and comforting to know that Orwell's 1984 is finally materializing]

(June 5, 2020) UK’s COVID-19 health data contracts with Google and Palantir finally emerge

Contracts for a number of coronavirus data deals that the U.K. government inked in haste with U.S. tech giants, including Google and Palantir, plus a U.K.-based AI firm called Faculty, have been published today by openDemocracy and law firm Foxglove — which had threatened legal action for withholding the information.

Concerns had been raised about what is an unprecedented transfer of health data on millions of U.K. citizens to private tech companies, including those with a commercial interest in acquiring data to train and build AI models. Freedom of Information requests for the contracts had been deferred up to now.

In a blog post today, openDemocracy and Foxglove write that the data store contracts show tech companies were “originally granted intellectual property rights (including the creation of databases), and were allowed to train their models and profit off their unprecedented access to NHS data.”

(June 5, 2020) Peter Thiel’s Palantir Is Given Access to U.K. Health Data on Covid-19 Patients

Britain’s National Health Service allowed secretive U.S. technology company Palantir Technologies Inc. access to sensitive personal data of patients, employees and members of the public under a deal to help it cope with the Covid-19 outbreak. Faculty, a London-based artificial intelligence firm, is also working on the NHS’s coronavirus response and secured access to sensitive data. Tech giants Microsoft Corp., Amazon Web Services and Google are also involved in the deal with the NHS. The companies are tasked with building a data platform to help understand how Covid-19 is spreading across the country and the capacity of its health-care system to deal with it. Faculty is run by Marc Warner, whose brother Ben Warner, a data scientist, worked with the Vote Leave Brexit campaign and has attended meetings of a scientific advisory group to guide the government on its coronavirus response strategy, the Guardian newspaper has reported.

(June 8, 2020) UK government releases details of COVID-19 data-sharing deals with big tech firms after legal action threat

Contracts released by the UK government have revealed that personal health information about millions of NHS patients was provided to private tech firms involved in the COVID-19 datastore project. Political website openDemocracy and tech justice firm Foxglove sent legal letters demanding transparency about the agreements, which were revealed hours before court proceedings were due to start on 5 June.

Details of the deals with Google, Amazon, Microsoft and Palantir and Faculty have been published online by openDemocracy. They reveal that companies involved in the datastore project were originally granted intellectual property rights and allowed to train their models and profit from access to NHS data, but the terms of the deal were changed after a Freedom of Information request made by Foxglove. 3jMMJcx

(July 22, 2020) With eyes on reopening, some colleges turn to saliva coronavirus tests for students

With demand for coronavirus testing expected to rise even higher this fall as students return to campuses across the nation, some major universities are adding their names to the list of those turning to at-home test kits that look for the virus in a person's saliva -- a novel technique that's raised hopes, and questions, when it comes to mass testing. “The current benefits outweigh the risks,” Purdue University Chief Medical officer Dr. Esteban Ramirez told ABC News. “The beauty of this is that we can screen and test everyone before they arrive on campus.”
Purdue officials said they plan to test every one of their 40,000 students with saliva kits prior to the fall semester.

(August 5, 2020) Blackstone Reaches $4.7 Billion Deal to Buy

Blackstone Group Inc. acquired a majority stake in Inc., the business known for family history research and DNA testing. It’s the first acquisition by Blackstone’s largest ever private equity fund. Silver Lake and Singaporean sovereign-wealth fund GIC Pte have been the majority owners since 2016. After the deal closes, Blackstone will own about 75% and GIC will still hold about 25% of,
said people familiar with the matter, who asked not to be identified because the information is private. Based in Lehi, Utah, has more than 3 million paying subscribers and more than 18 million people in its DNA network. It sells at-home DNA testing kits to customers, competing with 23andMe Inc.

(August 12, 2020) Alphabet’s Verily opens own lab to speed up COVID testing
In a blog post, Verily, Alphabet's life sciences research arm and a sister company to Google, has set up its own CLIA-certified lab (i.e., it has clinical laboratory credentials) and used tech from Thermo Fisher Scientific’s; TaqPath test kit, which has an emergency use tag (EUA) from the FDA, to test for COVID-19. It’s also sent off an EUA application for an adaptation of the TaqPath test for use in testing pooled patient specimens, which can further speed up testing. And it’s “verified” the Roche Elecsys Anti-SARS-CoV-2 antibody test, which can assess if you’ve had the disease (rather than currently have it), with plans to “implement additional tests in our lab,” said Deb Hanks, M.D., lead pathologist at Verily, in the blog post.

(August 24, 2020) QIAGEN to Launch Easy-to-Use Digital Test in the U.S. for Rapid Detection of SARS-CoV-2 Antibodies Following FDA Emergency Use Authorization

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of the new Access Anti-SARS-CoV-2 Total test, an easy-to-use digital test done on a portable device that provides results in about 10 minutes to detect antibodies in people exposed to the SARS-CoV-2 virus, which is the case of COVID-19. The launch of this antibody test, which was developed in partnership with the Australian digital diagnostics company Ellume, comes after the submission by QIAGEN of this unique antibody test to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA). First shipments are planned for late August 2020. A CE-IVD marking for Europe and other markets is planned in the coming weeks. The new serological test has been shown to have sensitivity of 100% (CI 88.43–100.00%) and specificity of 100% (CI 95.20–100.00%). The nanoparticle fluorescent detection technology uses serum or plasma from patient samples.

August 25, 2020) Fluidigm Granted FDA Emergency Use Authorization for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19

SOUTH SAN FRANCISCO, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the Advanta™ Dx SARS-CoV-2 RT-PCR Assay, an extraction-free saliva-based test to detect nucleic acid from the SARS-CoV2 virus, designed to be run on the Fluidigm® Biomark™ HD microfluidics platform.

(September 23, 2020) Privacy Fears Rising as DNA Test Companies Shift to New Ventures

At-home DNA test kits from companies like 23andMe and Ancestry have enabled customers to trace their heritage and piece together family trees. A lack of strict data privacy protections has allowed these companies to rack up hundreds of millions in revenue through the collection of DNA samples and sales of genetic data, all with the consent of customers who may not have read the fine print. As it stands, there is no comprehensive federal privacy law in the U.S. Other laws, including HIPPA and the Genetic Information Discrimination Act, only keep genetic information off-limits to certain types of insurers and employers.
Further, the agency that is supposed to enforce privacy rules by DNA testing companies, the Federal Trade Commission, has limited authority.

Exposed genetic information poses risks from the mundane to the extreme, experts say. Long-term care, disability and life insurers, for example, can still legally inflate their rates based on a customer’s predisposition to adverse health conditions. And if a person takes a DNA test, the information could be used to profile unsuspecting relatives as well. Some have warned of more dire consequences. One DNA data security startup, Geneinfosec—which counts former U.S. assistant secretary of defense Andrew C. Weber among its advisors—claims that someone’s DNA profile could be used as blackmail, or even to create bioweapons that target specific people. In 2019, Pentagon officials advised military troops to avoid taking consumer DNA tests because they could, “create unintended security consequences and increased risk to the joint force and mission.”

(October 15, 2020) Google & Oracle to Monitor Americans Who Get Warp Speed’s Covid-19 Vaccine for up to Two Years

During an interview with the Wall Street Journal published last Friday, the “captain” of Operation Warp Speed, career Big Pharma executive Moncef Slaoui, confirmed that the millions of Americans who are set to receive the project’s Covid-19 vaccine will be monitored via “incredibly precise . . . tracking systems” that will “ensure that patients each get two doses of the same vaccine and to monitor them for adverse health effects.” Slaoui also noted that tech giants Google and Oracle have been contracted as part of this “tracking system”
but did not specify their exact roles beyond helping to “collect and track vaccine data.” The day before the Wall Street Journal interview was published, the New York Times published a separate interview with Slaoui
where he referred to this “tracking system” as a “very active pharmacovigilance surveillance system.”

(October 21, 2020) Stanford Medicine launches home COVID-19 testing study covering greater San Francisco

Stanford University and its school of medicine have launched plans to survey the population of greater San Francisco for COVID-19, in an effort to build an early warning system for future outbreaks. The program is currently seeking to enroll participants, who will report their exposures and symptoms daily through an online portal.
Home test kits—developed in collaboration with the Chan Zuckerberg Biohub, which is also helping to fund the study—will be delivered through the mail within 24 hours at no cost, and will contain a gentle nasal swab for self-collection.

(October 30, 2020) Verily's COVID-19 testing program halted in San Francisco and Oakland

In a June letter (PDF) to California Secretary of Health Mark Ghaly, Oakland Mayor Libby Schaaf and other members of the county’s COVID-19 Racial Disparities Task Force raised numerous concerns about the Verily protocols. Among their complaints: People signing up for a test through Verily had to do so online, using an existing or newly created Gmail account; the sign-ups were offered only in English or Spanish; and participants were asked to provide sensitive personal information, including their home address and whether they were managing chronic health conditions such as diabetes, obesity or congestive heart failure, which could expose their data to third-party use.

[Note: Verily is a subsidiary of Google’s parent company Alphabet]

(December 4, 2020) New CRISPR-Based Test for COVID-19 Uses a Smartphone Camera

In a new study published in the scientific journal Cell, the team from Gladstone, UC Berkeley, and UCSF has outlined the technology for a CRISPR-based test for COVID-19 that uses a smartphone camera to provide accurate results in under 30 minutes. The technique was designed in collaboration with UC Berkeley bioengineer Daniel Fletcher, PhD, as well as Jennifer Doudna, PhD, who is a senior investigator at Gladstone, a professor at UC Berkeley, president of the Innovative Genomics Institute, and an investigator of the Howard Hughes Medical Institute. Doudna recently won the 2020 Nobel Prize in Chemistry for co-discovering CRISPR-Cas genome editing, the technology that underlies this work. "When coupled with repeated testing, measuring viral load could help determine whether an infection is increasing or decreasing,"
says Fletcher, who is also a Chan Zuckerberg Biohub Investigator.

(December 28, 2020) 23andMe Raises More Than $80 Million in Equity Financing Round

DNA testing company 23andMe Inc. raised more than $80 million in equity in a financing round led by Sequoia Capital and NewView Capital. According to Securities and Exchanges Commission filings, the company offered $85 million in equity and sold about $82.5 million. Previously, the company had raised about $791 million. In recent years, 23andMe has begun moving beyond telling individual consumers about their DNA and begun work developing therapeutics based on research into genetic information its customers provide. For example, the company has used its data to find genetic differences
that can affect a person’s susceptibility to Covid-19


Posts : 85
Join date : 2020-09-18

Back to top Go down

THE COVID-19 TIMELINE 1980 - 2020 Empty Re: THE COVID-19 TIMELINE 1980 - 2020

Post by Kerstin Sun Feb 14, 2021 3:15 am

to be continued.. (2021)

However, the truth behind this operation is that coronavirus was funded and patented by the "Wellcome Trust" which is owned by GlaxoSmithCline, Bill & Melinda Gates Foundation, DARPA, DEFRA (UK), Wor.

The Coronavirus patent was issued in just 17 months from initial filing - that’s almost unheard of speed - with very little objection back from SERCO UK-managed patent examiner Bao Q. Li coronavirus 4

List of patents assigned to the PIRBRIGHT INSTITUTE (funded by Wellcome Trust, Bill & Melinda Gates Foundation, EU & DARPA) The Pirbright Institute (Woking GB). (Compiled Jan. 28, 2020). Coronavirus et al Patent Assignee for Pat. Nos. 10,507,237; 10,294,277; 10,202,578; 10,130,701; 9,969,777; 9,457,075; 9,243,230; 9,145,548; 8,828,407; 8,501,466; 8,455,201. U.S. Patent Office.

why hasn't any corona virus ever been properly isolated?

How come the primers used in the PCR-tests test positive for (among other things) a wide range of bacteria that are naturally found in our body, as well as for parts of our own DNA?

Why did almost all governments around the world go along with the Rockefeller Foundation's 2010 OPERATION LOCK-STEP? Read for yourself starting on page 16 and pay close attention to what is described on page 19. (That's the world we're living in now):

Posts : 85
Join date : 2020-09-18

Back to top Go down

THE COVID-19 TIMELINE 1980 - 2020 Empty Re: THE COVID-19 TIMELINE 1980 - 2020

Post by Sponsored content

Sponsored content

Back to top Go down

Back to top

Permissions in this forum:
You cannot reply to topics in this forum